| Name | Title | Contact Details |
|---|---|---|
Christopher Guidry |
Chief Technical Officer | Profile |
Color provides a high-quality, physician-ordered, genetic test at a low cost. We include support for physicians, as well as genetic counseling as part of every purchase. Our goal is to expand physician-supported access to genetic testing for hereditary cancer risk to every person, everywhere.
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in Boston`s innovation district to support the U.S. launch of Auryxia. Patients have been and continue to be at the center of our nearly 20 year corporate history.
Epicentre Technologies Corp is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Learn more about Cara Therapeutics, a biotechnology company focusing on pharmaceutical product development for better pruritus and pain management.
Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.